Streetbeat News

Analyst Ratings

AMN

B of A Securities has downgraded AMN Healthcare Services from Neutral to Underperform and reduced its price target from $65 to $48.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 11:09 am

BKD

B of A Securities has downgraded Brookdale Senior Living (NYSE:BKD) from Neutral to Underperform and reduced its price target from $7.75 to $6.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 11:06 am

SMTC

Benchmark analyst Cody Acree has reiterated a Buy rating on Semtech (NASDAQ:SMTC) and maintained a price target of $56.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 11:04 am

KALV

HC Wainwright & Co. has reiterated its Buy rating for KalVista Pharma, maintaining a price target of $20. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:58 am

DMAC

HC Wainwright & Co. has initiated coverage on DiaMedica Therapeutics with a Buy rating and set a price target of $7.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:52 am

EU

HC Wainwright & Co. has reiterated its Buy rating for enCore Energy, maintaining a price target of $7. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:45 am

BNTX

HC Wainwright & Co. has maintained a Buy rating on BioNTech and raised its price target from $113 to $150, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:42 am

ARI

EFC

RC

The article highlights three oversold financial stocks with potential for short-term gains: Apollo Commercial Real Estate Finance Inc (ARI), Ready Capital Corp (RC), and Ellington Financial Inc (EFC). These stocks have RSI values near or below 30, indicating they are oversold. ARI posted strong earnings but saw a 13% decline in stock price over the past month. RC had its price target lowered by Piper Sandler, with a 7% decline in stock price. EFC reported weaker-than-expected earnings, with a 5% decline in stock price.

Portfolio Pulse from Avi Kapoor

October 07, 2024 | 10:42 am

RYTM

HC Wainwright & Co. has reiterated its Buy rating for Rhythm Pharmaceuticals, maintaining a price target of $64. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:32 am

ENTX

HC Wainwright & Co. has reiterated its Buy rating on Entera Bio (NASDAQ:ENTX) and maintained a price target of $10, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:31 am